Aclarion Raises $4.7M to Advance AI-Powered Chronic Back Pain Technology

Healthcare technology company Aclarion, Inc. (Nasdaq: ACON, ACONW) has announced a $4.7 million registered direct offering of common stock, positioning the company to advance its AI-powered platform for chronic back pain diagnosis. The company will sell 506,803 shares at $9.25 per share, with the transaction expected to close by January 31, 2025.

The funding comes at a crucial time in healthcare technology development, particularly in the field of chronic pain management. Aclarion's flagship product, Nociscan, represents a significant advancement in back pain diagnosis by using Magnetic Resonance Spectroscopy (MRS) and AI algorithms to help physicians differentiate between painful and non-painful spinal discs – a distinction that has traditionally been challenging to make with conventional imaging methods.

This capital injection will support market development, clinical evidence gathering, and product development, potentially accelerating the adoption of more precise diagnostic tools in spine care. For the estimated millions of Americans suffering from chronic back pain, this technology could lead to more targeted and effective treatment strategies by providing physicians with clearer insights into pain sources.

The offering, managed by Dawson James Securities, Inc., is being conducted under a shelf registration statement that received SEC approval in September 2024. This funding round demonstrates growing investor confidence in AI-powered medical diagnostic tools and could signal a shift toward more data-driven approaches in pain management.